Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS884448 in Combination with Standard of Care or Investigational Therapies in Advanced Solid Tumors
2024-512227-36-00Phase 2Completed
- Sponsor
- iTeos Therapeutics
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of feladilimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more (7 arms), sponsored by iTeos Therapeutics. Primary endpoints: Safety and tolerability (Part 1 dose finding), Overall response rate (Part 2 expansion) and 1 more. Started Nov 2024; status: completed.
02
Drugs
feladilimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-512227-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512227-36-00.